Article

Biovitrum study to target glaucoma

Biovitrum, a Stockholm-based biopharmaceutical company, has initiated a clinical phase II study with the candidate drug BVT.28949, a 5-HT2A antagonist for treating glaucoma.

Biovitrum, a Stockholm-based biopharmaceutical company, has initiated a clinical phase II study with the candidate drug BVT.28949, a 5-HT2A antagonist for treating glaucoma.

The placebo-controlled study of 150 patients with elevated IOP will be conducted at several clinics in Sweden and the Ukraine next spring. Results are expected in mid-2007.

The company believes that BVT.28949 reduces IOP by stimulating the outflow of aqueous humor through the trabecular meshwork, unlike prostaglandins. The eye drops could function alone or in combination with existing products, according to the company.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.